| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment
|
Robinson, Philip C
|
|
|
|
11 |
p. e653-e655
|
artikel
|
| 2 |
Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies
|
Boekel, Laura
|
|
|
|
11 |
p. e778-e788
|
artikel
|
| 3 |
Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination
|
Frey, Sarah
|
|
|
|
11 |
p. e753-e754
|
artikel
|
| 4 |
Autoantigens in rheumatoid arthritis and the potential for antigen-specific tolerising immunotherapy
|
Nel, Hendrik J
|
|
|
|
11 |
p. e712-e723
|
artikel
|
| 5 |
A wake-up call for sleep in rheumatic diseases
|
The Lancet Rheumatology,
|
|
|
|
11 |
p. e739
|
artikel
|
| 6 |
Back pain: a target for reducing hospital admissions?
|
Machado, Gustavo C
|
|
|
|
11 |
p. e643-e645
|
artikel
|
| 7 |
B cells: more than just for antibodies in SARS-CoV-2 vaccine responses
|
Paley, Michael A
|
|
|
|
11 |
p. e741-e743
|
artikel
|
| 8 |
Beyond very early systemic sclerosis: deciphering pre‑scleroderma and its trajectories to open new avenues for preventive medicine
|
Lescoat, Alain
|
|
|
|
11 |
p. e683-e694
|
artikel
|
| 9 |
Bilateral anterior non-necrotising scleritis, anterior uveitis, and unilateral facial nerve palsy in paediatric inflammatory multisystem syndrome temporally associated with COVID-19
|
Islam, Meriam
|
|
|
|
11 |
p. e818
|
artikel
|
| 10 |
Composite endpoints for Sjögren's Syndrome
|
Baicus, Cristian
|
|
|
|
11 |
p. e751
|
artikel
|
| 11 |
Composite endpoints for Sjögren's Syndrome
|
Yildirim, Derya
|
|
|
|
11 |
p. e751-e752
|
artikel
|
| 12 |
Composite endpoints for Sjögren's Syndrome – Authors' reply
|
de Wolff, Liseth
|
|
|
|
11 |
p. e752-e753
|
artikel
|
| 13 |
Correction to Lancet Rheumatol 2020; 2: e99–109
|
|
|
|
|
11 |
p. e664
|
artikel
|
| 14 |
COVID-19: is the rush to boost backed by science?
|
The Lancet Rheumatology,
|
|
|
|
11 |
p. e737
|
artikel
|
| 15 |
COVID-19 vaccine effectiveness against omicron (B.1.1.529) variant infection and hospitalisation in patients taking immunosuppressive medications: a retrospective cohort study
|
Risk, Malcolm
|
|
|
|
11 |
p. e775-e784
|
artikel
|
| 16 |
Current issues in rheumatoid arthritis-associated interstitial lung disease
|
Kelly, Clive
|
|
|
|
11 |
p. e798-e807
|
artikel
|
| 17 |
Cutaneous vasculitis following COVID-19 vaccination
|
Cavalli, Giulio
|
|
|
|
11 |
p. e743-e744
|
artikel
|
| 18 |
Efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomised, placebo-controlled, proof-of-concept trial
|
Marsman, Diane E
|
|
|
|
11 |
p. e758-e766
|
artikel
|
| 19 |
Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study
|
Buckley, Christopher D
|
|
|
|
11 |
p. e677-e688
|
artikel
|
| 20 |
Embracing holistic management in SLE
|
The Lancet Rheumatology,
|
|
|
|
11 |
p. e639
|
artikel
|
| 21 |
Encouraging data on rituximab in polymyalgia rheumatica
|
Sandovici, Maria
|
|
|
|
11 |
p. e738-e739
|
artikel
|
| 22 |
Familial chilblain lupus with TREX1 mutation and cerebrovascular disease
|
Nohara, Takuma
|
|
|
|
11 |
p. e724
|
artikel
|
| 23 |
FDA expands JAK inhibitors warning: going beyond the data?
|
Thorley, Jennifer
|
|
|
|
11 |
p. e757
|
artikel
|
| 24 |
Genetic variants mimicking therapeutic inhibition of IL-6 receptor signaling and risk of COVID-19
|
Bovijn, Jonas
|
|
|
|
11 |
p. e658-e659
|
artikel
|
| 25 |
Global, regional, and national burden of other musculoskeletal disorders, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021
|
|
|
|
|
11 |
p. e670-e682
|
artikel
|
| 26 |
Haemophagocytic lymphohistiocytosis secondary to COVID-19: a case series
|
Flower, Luke
|
|
|
|
11 |
p. e744-e747
|
artikel
|
| 27 |
Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study
|
Moor, Matthias B
|
|
|
|
11 |
p. e789-e797
|
artikel
|
| 28 |
Immunocompromised patients in the USA and UK should receive third dose of COVID-19 vaccine
|
Furlow, Bryant
|
|
|
|
11 |
p. e756
|
artikel
|
| 29 |
Increased risk of severe COVID-19 outcomes in patients with rheumatoid arthritis and interstitial lung disease
|
Kelly, Clive
|
|
|
|
11 |
p. e741-e743
|
artikel
|
| 30 |
Inflammatory myositis after ChAdOx1 vaccination
|
Maramattom, Boby Varkey
|
|
|
|
11 |
p. e747-e749
|
artikel
|
| 31 |
Interpreting big-data analysis of retrospective observational data
|
Huizinga, Tom W J
|
|
|
|
11 |
p. e652-e653
|
artikel
|
| 32 |
Jean Liew: from Bronte scholar to social media influencer
|
Thorley, Jennifer
|
|
|
|
11 |
p. e754
|
artikel
|
| 33 |
Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study
|
Gentry, Chris A
|
|
|
|
11 |
p. e689-e697
|
artikel
|
| 34 |
Mavrilimumab for severe COVID-19
|
Khan, Adil Rashid
|
|
|
|
11 |
p. e661-e662
|
artikel
|
| 35 |
Mavrilimumab for severe COVID-19
|
Pourhoseingholi, Mohamad Amin
|
|
|
|
11 |
p. e662
|
artikel
|
| 36 |
Mavrilimumab for severe COVID-19 – Authors' reply
|
De Luca, Giacomo
|
|
|
|
11 |
p. e662-e663
|
artikel
|
| 37 |
Monkeypox associated acute arthritis
|
Fonti, Mirella
|
|
|
|
11 |
p. e804
|
artikel
|
| 38 |
MRI of the joint and evaluation of the granulocyte–macrophage colony-stimulating factor–CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study
|
Genovese, Mark C
|
|
|
|
11 |
p. e666-e676
|
artikel
|
| 39 |
Ngozi Chiejina: perseverance in the face of adversity
|
Morgan, Jules
|
|
|
|
11 |
p. e647
|
artikel
|
| 40 |
Omicron breakthrough infections in patients with immune-mediated inflammatory diseases
|
Liew, Jean W
|
|
|
|
11 |
p. e751-e752
|
artikel
|
| 41 |
Polychondritis in a child
|
Gu, Yudan
|
|
|
|
11 |
p. e695-e696
|
artikel
|
| 42 |
Precision medicine in juvenile idiopathic arthritis—has the time arrived?
|
Reiff, Daniel D
|
|
|
|
11 |
p. e808-e817
|
artikel
|
| 43 |
Predicting outcomes in systemic sclerosis by skin involvement and autoantibodies
|
Pope, Janet E
|
|
|
|
11 |
p. e745-e747
|
artikel
|
| 44 |
Preventive medicine in rheumatology: COVID-19 and its lessons for better health outcomes
|
Liew, David F L
|
|
|
|
11 |
p. e743-e745
|
artikel
|
| 45 |
Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease
|
Hughes, Michael
|
|
|
|
11 |
p. e795-e803
|
artikel
|
| 46 |
Research in Brief
|
Thorley, Jennifer
|
|
|
|
11 |
p. e753
|
artikel
|
| 47 |
Research in Brief
|
Thorley, Jennifer
|
|
|
|
11 |
p. e755
|
artikel
|
| 48 |
Research in Brief
|
Thorley, Jennifer
|
|
|
|
11 |
p. e665
|
artikel
|
| 49 |
Research in Brief
|
Thorley, Jennifer
|
|
|
|
11 |
p. e646
|
artikel
|
| 50 |
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial
|
Distler, Oliver
|
|
|
|
11 |
p. e660-e669
|
artikel
|
| 51 |
Riociguat in systemic sclerosis: challenges in crossing the bridge from bench to bedside
|
de Vries-Bouwstra, Jeska K
|
|
|
|
11 |
p. e641-e643
|
artikel
|
| 52 |
Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study
|
Lane, Jennifer C E
|
|
|
|
11 |
p. e698-e711
|
artikel
|
| 53 |
Risk of severe COVID-19 outcomes associated with rheumatoid arthritis and phenotypic subgroups: a retrospective, comparative, multicentre cohort study
|
Figueroa-Parra, Gabriel
|
|
|
|
11 |
p. e765-e774
|
artikel
|
| 54 |
SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period
|
Boekel, Laura
|
|
|
|
11 |
p. e747-e750
|
artikel
|
| 55 |
Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort
|
Elhai, Muriel
|
|
|
|
11 |
p. e785-e794
|
artikel
|
| 56 |
Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials
|
Rivellese, Felice
|
|
|
|
11 |
p. e648-e659
|
artikel
|
| 57 |
Surgical microdiscectomy versus transforaminal epidural steroid injection in patients with sciatica due to lumbar disc herniation
|
Tiwari, Vivek
|
|
|
|
11 |
p. e750
|
artikel
|
| 58 |
Surgical microdiscectomy versus transforaminal epidural steroid injection in patients with sciatica due to lumbar disc herniation – Authors' reply
|
Wilby, Martin John
|
|
|
|
11 |
p. e750-e751
|
artikel
|
| 59 |
Suspending methotrexate for 2 weeks after COVID-19 vaccination
|
Coates, Laura C
|
|
|
|
11 |
p. e740-e741
|
artikel
|
| 60 |
Synovial tissue for personalised medicine in rheumatoid arthritis: hype or hope?
|
van der Helm-van Mil, Annette H
|
|
|
|
11 |
p. e640-e641
|
artikel
|
| 61 |
Tapering and withdrawal in patients with rheumatoid arthritis in stable remission
|
Hill, Catherine L
|
|
|
|
11 |
p. e739-e741
|
artikel
|
| 62 |
The contribution of the observational research design to COVID-19 research
|
Kim, Alfred H J
|
|
|
|
11 |
p. e650-e652
|
artikel
|
| 63 |
The efficacy and safety of targeting GM-CSF in arthritis
|
Bykerk, Vivian P
|
|
|
|
11 |
p. e648-e650
|
artikel
|
| 64 |
Tocilizumab for severe COVID-19 pneumonia
|
Mourad, Jean-Jacques
|
|
|
|
11 |
p. e659
|
artikel
|
| 65 |
Tocilizumab for severe COVID-19 pneumonia
|
Piano, Salvatore
|
|
|
|
11 |
p. e659-e660
|
artikel
|
| 66 |
Tocilizumab for severe COVID-19 pneumonia
|
Lipworth, Brian J
|
|
|
|
11 |
p. e660
|
artikel
|
| 67 |
Tocilizumab for severe COVID-19 pneumonia – Authors' reply
|
Guaraldi, Giovanni
|
|
|
|
11 |
p. e660-e661
|
artikel
|
| 68 |
Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial
|
Tascilar, Koray
|
|
|
|
11 |
p. e767-e777
|
artikel
|
| 69 |
Viral arthritis and COVID-19
|
Parisi, Simone
|
|
|
|
11 |
p. e655-e657
|
artikel
|
| 70 |
Voting to end the American healthcare nightmare
|
The Lancet Rheumatology,
|
|
|
|
11 |
p. e647
|
artikel
|
| 71 |
Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised controlled trials
|
Skaria, Teny Grace
|
|
|
|
11 |
p. e755-e764
|
artikel
|
Tijdschrift beschrijving